SCHEMBL4385353

SCHEMBL4385353

Sc1ncnc2nccnc12

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007375 0.75 ADORA2A (0.52) ADORA2A
SCHEMBL8082857 0.70 ADORA2A (0.32) ADORA2A
SCHEMBL314773 0.70 ADORA2A (0.32) ADORA2A
SCHEMBL314774 0.70 ADORA2A (0.32) ADORA2A
SCHEMBL2007373 0.70 ADORA2A (0.32) ADORA2A
SCHEMBL28188932 0.70 ADORA2A (0.37) ADORA2A
SCHEMBL4386487 0.70 ADORA2A (0.33) ADORA2A
SCHEMBL10029635 0.65 FFAR2 (0.31)
SCHEMBL2013871 0.65
SCHEMBL10029624 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200147076-A1 PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME PLATFORM BRIGHTWORKS TWO, LTD. (US) 2020-05-14 US claimed
US-20180296556-A1 PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME PLATFORM BRIGHTWORKS TWO, LTD. (US) 2018-10-18 US claimed
US-20170172971-A1 PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME PLATFORM BRIGHTWORKS TWO, LTD. (US) 2017-06-22 US claimed
EP-2701684-A1 IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME Board Of Regents, The University Of Texas System (US) 2014-03-05 EP claimed
WO-2012148799-A1 IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-11-01 WO claimed
US-20120277249-A1 PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME GREENJAY THERAPEUTICS, INC. 2012-11-01 US claimed
EP-0483426-A1 Thiol heterocyclic deodorant composition and method of deodorization THE PROCTER & GAMBLE COMPANY (US) 1992-05-06 EP claimed
US-20250325494-A1 COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID THEMEDIUM THERAPEUTICS CO., LTD. (CN) 2025-10-23 US disclosed
US-20250228788-A1 COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-07-17 US disclosed
US-20250188013-A1 LIPID COMPOUND AND USE THEREOF THEMEDIUM THERAPEUTICS CO., LTD. (CN) 2025-06-12 US disclosed
CN-112996519-B Compositions and methods for organ-specific delivery of nucleic acids 德克萨斯大学系统董事会 2025-02-28 CN disclosed
CN-119421870-A Lipid compound and application thereof 传信生物医药(苏州)有限公司 2025-02-11 CN disclosed
CN-119384273-A Organ-specific delivery compositions for nucleic acids 传信生物医药(苏州)有限公司 2025-01-28 CN disclosed
US-20110054173-A1 PTERIDINES AND THEIR USE AS AGROCHEMICALS DOW AGROSCIENCES LLC (US) 2011-03-03 US disclosed
US-20110054173-A1 PTERIDINES AND THEIR USE AS AGROCHEMICALS DOW AGROSCIENCES LLC (US) 2011-03-03 US disclosed
CN-101636148-A Linker-based lecithin microemulsion delivery vehicle JOEL ACOSTA-ZARA EDGAR 2010-01-27 CN disclosed
EP-2120871-A1 LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES Acosta-Zara, Edgar, Joel (CA) 2009-11-25 EP disclosed
WO-2008070961-A1 LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES ACOSTA-ZARA EDGAR JOEL (CA) 2008-06-19 WO disclosed
US-20080139392-A1 Linker-Based Lecithin Microemulsion Delivery Vehicles ACOSTA-ZARA EDGAR JOEL 2008-06-12 US disclosed
EP-0483426-A1 Thiol heterocyclic deodorant composition and method of deodorization THE PROCTER & GAMBLE COMPANY (US) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250228788-A1 COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS POLRMT, FABP1, SNRPE ADORA2A 2809/4885
US-20250325494-A1 COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID FABP1, POLRMT, LIPC ADORA2A 3128/4885
US-20110054173-A1 PTERIDINES AND THEIR USE AS AGROCHEMICALS PIR, PFAS, PNPO ADORA2A 1213/4885
US-20250188013-A1 LIPID COMPOUND AND USE THEREOF NPC1L1, CYP46A1, PCSK9 ADORA2A 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.